| An R package suite for microarray meta-analysis in quality control, differentially expressed gene analysis and pathway enrichment detection X Wang, DD Kang, K Shen, C Song, S Lu, LC Chang, SG Liao, Z Huo, ... Bioinformatics 28 (19), 2534-2536, 2012 | 209 | 2012 |
| Missing value imputation in high-dimensional phenomic data: imputable or not, and how? SG Liao, Y Lin, DD Kang, D Chandra, J Bon, N Kaminski, FC Sciurba, ... BMC bioinformatics 15, 1-12, 2014 | 146 | 2014 |
| Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 134, 570, 2019 | 81 | 2019 |
| The molecular landscape of premenopausal breast cancer S Liao, RJ Hartmaier, KP McGuire, SL Puhalla, S Luthra, UR Chandran, ... Breast Cancer Research 17, 1-13, 2015 | 77 | 2015 |
| Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic … AM Brunner, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 136, 1-2, 2020 | 76 | 2020 |
| Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven … A Bardia, M Parton, S Kümmel, LG Estévez, CS Huang, J Cortés, ... Journal of Clinical Oncology 36 (31), 3126-3133, 2018 | 61 | 2018 |
| Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer PY Yan, Y Ding, R Chen, SG Liao, BG Ren, A Michalopoulos, ... The American journal of pathology 183 (6), 1960-1970, 2013 | 51 | 2013 |
| Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors. A Calvo, H Joensuu, M Sebastian, A Naing, YJ Bang, M Martin, D Roda, ... Journal of Clinical Oncology 36 (15_suppl), 3014-3014, 2018 | 40 | 2018 |
| Bias correction for selecting the minimal-error classifier from many machine learning models Y Ding, S Tang, SG Liao, J Jia, S Oesterreich, Y Lin, GC Tseng Bioinformatics 30 (22), 3152-3158, 2014 | 33 | 2014 |
| Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition TA Katz, SG Liao, VJ Palmieri, RK Dearth, TN Pathiraja, Z Huo, P Shaw, ... Cancer prevention research 8 (10), 1000-1009, 2015 | 23 | 2015 |
| Abstract P5-21-04: Phase I/Ib study of the SERD LSZ102 alone or in combination with ribociclib in ER+ breast cancer D Juric, G Curigliano, S Cresta, YS Yap, C Terret, FP Duhoux, ... Cancer research 78 (4_Supplement), P5-21-04-P5-21-04, 2018 | 14 | 2018 |
| Sabatolimab (MBG453) dose selection and dose-response analysis in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML): population pharmacokinetics (PK) modeling and … AH Wei, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 136, 40-42, 2020 | 9 | 2020 |
| A Phase 3, Open-Label, Multicenter Study To Evaluate Eculizumab In Adolescents With Refractory Generalized Myasthenia Gravis (S5. 009) JF Brandsema, M Ginsberg, H Hoshino, M Mimaki, S Nagata, V Rao, ... Neurology 100 (17 Supplement 2), 2023 | 6 | 2023 |
| Abstract PD7-09: A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive … K Jhaveri, D Juric, S Cresta, YS Yap, FP Duhoux, C Terret, R Layman, ... Cancer Research 80 (4_Supplement), PD7-09-PD7-09, 2020 | 5 | 2020 |
| Considerations and pitfalls in phenotyping and reclassification of chronic obstructive pulmonary disease J Bon, S Liao, G Tseng, FC Sciurba Translational Research 162 (4), 252-257, 2013 | 5 | 2013 |
| RNASeqDesign: a framework for ribonucleic acid sequencing genomewide power calculation and study design issues CW Lin, SG Liao, P Liu, MLT Lee, YS Park, GC Tseng Journal of the Royal Statistical Society Series C: Applied Statistics 68 (3 …, 2019 | 3 | 2019 |
| Ravulizumab for the treatment of generalized myasthenia gravis: timing of response AA Habib, M Benatar, T Vu, A Meisel, S Attarian, M Katsuno, S Liao, ... MUSCLE & NERVE 66, S125-S125, 2022 | 2 | 2022 |
| Abstract PD1-08: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with … K Jhaveri, G Curigliano, YS Yap, S Cresta, FP Duhoux, C Terret, ... Cancer research 79 (4_Supplement), PD1-08-PD1-08, 2019 | 2 | 2019 |
| Achievement of improved post-intervention status in patients with generalized myasthenia gravis treated with ravulizumab during the CHAMPION MG study (S5. 008) S Muppidi, P Narayanaswami, A Meisel, T Vu, K Utsugisawa, ... Neurology 100 (17 Supplement 2), 2023 | 1 | 2023 |
| Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+ … G Curigliano, S Cresta, YS Yap, D Juric, FP Duhoux, C Terret, ... Cancer Research 79 (4_Supplement), OT1-03-01-OT1-03-01, 2019 | 1 | 2019 |
